---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-230710"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2024-10-02T23:59:59+00:00"
generated_at: "2026-05-30T22:14:28.471264+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions closes $100M ABL credit facility, reports $150M cash balance

## Summary
- New asset-based revolving loan facility of up to $100M, maturing September 2029.
- Cash balance of approximately $150M as of September 30, 2024.
- ABL facility undrawn at closing; provides additional liquidity for transformation plan.
- Facility follows prior $250M term loan refinancing with Oak Hill Advisors in September 2024.

## SEC filing metadata
- accession: 0001193125-24-230710
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2024-10-02T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000119312524230710/0001193125-24-230710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000119312524230710/d825659d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-230710
- JSON: https://secwatch.observer/filing/0001193125-24-230710.json
- Plain text: https://secwatch.observer/filing/0001193125-24-230710.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.